Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2012-000043-27 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric upper limb spasticity.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BOTOX® | Experimental | Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Botulinum Toxin Type A | Biological | Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With at Least One Treatment- Emergent Adverse Event (TEAE) | An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A TEAE was an AE that occurred after receiving the first dose of investigational product or an AE present prior to first dose but increased in severity during the Treatment Period. Safety population included all treated participants. | From first dose of study drug up to 12 weeks post last dose (Up to 60 weeks) |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Emily McCusker | Allergan | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ABS Health, LLC | Pasadena | California | 91106 | United States | ||
| Harrison Clinical Management |
Not provided
| Label | URL |
|---|---|
| More information | View source |
Not provided
Pediatric participants with Upper Limb Spasticity who were previously treated with BOTOX® in study 191622-101 [NCT01603602] and de novo participants received up to 5 BOTOX® treatments in this study.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | BOTOX® | Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Aug 1, 2016 | Jul 29, 2019 |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Pomona |
| California |
| 91767 |
| United States |
| Rady Children's Hospital San Diego | San Diego | California | 92123 | United States |
| Children's Hospital Colorado Dept. of PM&R | Aurora | Colorado | 80045 | United States |
| Associated Neurologists of Southern Connecticut, P.C. | Fairfield | Connecticut | 06824 | United States |
| New England Center for Clinical Research | Stamford | Connecticut | 06905 | United States |
| NW FL Clinical Research Group, LLC | Gulf Breeze | Florida | 32561 | United States |
| Axcess Medical Research, LLC | Loxahatchee Groves | Florida | 33470 | United States |
| Pediatric Neurology, PA | Orlando | Florida | 32891 | United States |
| Children's Healthcare of Atlanta Children's Rehabilitation Associates | Atlanta | Georgia | 30342 | United States |
| Gillette Children's Specialty Healthcare | Saint Paul | Minnesota | 55101 | United States |
| The Children's Mercy Hospital & Clinics | Kansas City | Missouri | 64108 | United States |
| Washington University School of Medicine | St Louis | Missouri | 63110 | United States |
| Clinical Research Center of New Jersey | Voorhees Township | New Jersey | 08043 | United States |
| NYU Hospital for Joint Diseases | New York | New York | 10003 | United States |
| Columbia University Pediatric Physical Medicine & Rehabilitation, Dept. of Rehabilitation & Regenerative Medicine Harkness | New York | New York | 10032 | United States |
| OnSite Clinical Solutions, LLC | Charlotte | North Carolina | 28203 | United States |
| PMG Research of Charlotte, LLC | Charlotte | North Carolina | 28203 | United States |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | United States |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75235 | United States |
| Baylor College of Medicine Texas Children's Hospital | Houston | Texas | 77030 | United States |
| Road Runner Research | San Antonio | Texas | 78249 | United States |
| Seattle Children's Hospital | Seattle | Washington | 98105 | United States |
| Marshfield Clinic | Marshfield | Wisconsin | 54449 | United States |
| Holland Bloorview Kids Rehab | Toronto | Ontario | M4G 1R8 | Canada |
| Debrecen University Clinical Center, Orthopedic Clinic | Debrecen | 4032 | Hungary |
| De La Salle Health Sciences Institute | Cavite | 4114 | Philippines |
| Philippine Children's Medical Center | Quezon City | 1104 | Philippines |
| Uni Centrum Kliniczne | Gdansk | 80-219 | Poland |
| Specjal. Gabinet Neurologiczny | Krakow | 30-539 | Poland |
| Centrum Medyczne "POMOC" | Lodz | 93-271 | Poland |
| INTERMED, Lublin | Lublin | 20-058 | Poland |
| CRH ŻAGIEL MED, Lublin | Lublin | 20-601 | Poland |
| Centrum Profilatyki I Terapii | Warsaw | 02-383 | Poland |
| NZOZ Mazowieckie Centrum | Warsaw | 05-462 | Poland |
| Childrens Republic Hospital | Kazan' | 420138 | Russia |
| Smolensk Regional Hospital- Regional Budget State Healthcare institution | Smolensk | 214018 | Russia |
| Tyumen Regional Hospital #2 - State Budget Healthcare Institution of Tyumen region | Tyumen | 625039 | Russia |
| Daegu Fatima Hospital | Daegu | 41199 | South Korea |
| National Health Insurance Service Ilsan Hospital | Gyeonggi-do | 10444 | South Korea |
| Seoul National University Hospital | Seoul | 03080 | South Korea |
| Severance Hospital, Yonsei University Health System | Seoul | 03722 | South Korea |
| Asan Medical Center | Seoul | 05505 | South Korea |
| Samsung Medical Center | Seoul | 06351 | South Korea |
| Siriraj Hospital Dept of Rehabilitation Medicine, Faculty of Medicine | Bangkok | 10700 | Thailand |
| Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University | Chiang Mai | 50200 | Thailand |
| Srinagarind Hospital, Khon Kaen University | Khon Kaen | 40002 | Thailand |
| Kocaeli Üniversitesi | Kocaeli | 41050 | Turkey (Türkiye) |
| Safety Population (Treated) |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Safety population included all treated participants.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | BOTOX® | Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants With at Least One Treatment- Emergent Adverse Event (TEAE) | An adverse event (AE) was any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A TEAE was an AE that occurred after receiving the first dose of investigational product or an AE present prior to first dose but increased in severity during the Treatment Period. Safety population included all treated participants. | Safety population included all treated participants. | Posted | Number | percentage of participants | From first dose of study drug up to 12 weeks post last dose (Up to 60 weeks) |
|
|
|
From first dose of study drug up to 12 weeks post last dose (Up to 60 weeks)
Safety population included all treated participants.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | BOTOX® | Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study. | 0 | 213 | 13 | 213 | 57 | 213 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cryptorchism | Congenital, familial and genetic disorders | MedDRA 19.0 | Systematic Assessment |
| |
| Food poisoning | Gastrointestinal disorders | MedDRA 19.0 | Systematic Assessment |
| |
| Dental caries | Gastrointestinal disorders | MedDRA 19.0 | Systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
| |
| Respiratory tract infection viral | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
| |
| Meningitis | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
| |
| Dehydration | Metabolism and nutrition disorders | MedDRA 19.0 | Systematic Assessment |
| |
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA 19.0 | Systematic Assessment |
| |
| Joint contracture | Musculoskeletal and connective tissue disorders | MedDRA 19.0 | Systematic Assessment |
| |
| Juvenile idiopathic arthritis | Musculoskeletal and connective tissue disorders | MedDRA 19.0 | Systematic Assessment |
| |
| Epilepsy | Nervous system disorders | MedDRA 19.0 | Systematic Assessment |
| |
| Hemiplegia | Nervous system disorders | MedDRA 19.0 | Systematic Assessment |
| |
| Seizure | Nervous system disorders | MedDRA 19.0 | Systematic Assessment |
| |
| Status epilepticus | Nervous system disorders | MedDRA 19.0 | Systematic Assessment |
| |
| Partial seizures | Nervous system disorders | MedDRA 19.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Upper respiratory tract infection | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA 19.0 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 19.0 | Systematic Assessment |
|
A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Therapeutic Area, Head | Allergan | 714-246-4500 | clinicaltrials@allergan.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jan 14, 2019 | Jul 29, 2019 | SAP_001.pdf |
| ID | Term |
|---|---|
| D009128 | Muscle Spasticity |
| D002547 | Cerebral Palsy |
| D020521 | Stroke |
| ID | Term |
|---|---|
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D009122 | Muscle Hypertonia |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001925 | Brain Damage, Chronic |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D002561 | Cerebrovascular Disorders |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D019274 | Botulinum Toxins, Type A |
| ID | Term |
|---|---|
| D001905 | Botulinum Toxins |
| D008666 | Metalloendopeptidases |
| D010450 | Endopeptidases |
| D010447 | Peptide Hydrolases |
| D006867 | Hydrolases |
| D004798 | Enzymes |
| D045762 | Enzymes and Coenzymes |
| D045726 | Metalloproteases |
| D001426 | Bacterial Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D001427 | Bacterial Toxins |
| D014118 | Toxins, Biological |
| D001685 | Biological Factors |
Not provided
Not provided
| Asian |
|
| Hispanic |
|
| Other |
|